
Amy Fowler Therapy Expands Services with Move to New State-of-the-Art Office Location in Fort Worth
Licensed Professional Counselor Associate brings specialized child, teen, women's, and couples therapy services to enhanced therapeutic space designed for healing and growth
FORT WORTH, TX – May 30, 2025 – Amy Fowler Therapy, a leading private practice specializing in counseling services for children, teens, women, and couples, announces its relocation to a new, purpose-built office at 3348 Peden Rd., Suite 407, Fort Worth, TX 76179. The move represents a significant expansion of the practice's ability to serve the North Texas community with enhanced therapeutic environments specifically designed to meet the unique needs of each client population.
Amy Fowler, a Licensed Professional Counselor Associate (LPCA) with over 17 years of experience working with children and adolescents and more than 10 years counseling women, has created a therapeutic space that reflects her commitment to providing exceptional mental health care in a welcoming, judgment-free environment. The new location significantly expands the practice's capacity to serve families throughout Fort Worth, Haslet, Keller, Saginaw, and surrounding communities.
The new office features thoughtfully designed spaces that cater to the diverse needs of Amy Fowler Therapy's clientele. The facility includes a spacious family waiting room where parents and caregivers can feel comfortable while their children receive treatment. This welcoming area acknowledges the important role families play in the therapeutic process and provides a relaxed environment for pre- and post-session discussions.
The centerpiece of the new location is a large, versatile counseling office that incorporates specialized sections for different therapeutic modalities. Understanding that children often express themselves best through play, the space includes dedicated areas for play therapy, allowing children to explore their emotions, thoughts, and experiences through activities like drawing, storytelling, and role-playing. Additionally, the office features a designated art therapy section, providing children with creative outlets to process their feelings and develop coping strategies in ways that traditional talk therapy might not achieve.
For adult clients, particularly women seeking counseling services and couples working to strengthen their relationships, the new space offers a calming environment specifically designed to promote healing and personal growth. Amy's extensive experience helping women overcome relationship challenges, parenting issues, self-identity concerns, workplace struggles, and grief, combined with her work helping couples navigate communication breakdowns, trust issues, emotional distance, and life transitions, has informed the creation of this therapeutic space, ensuring that every element supports the journey toward wholeness and emotional well-being.
Amy Fowler holds a Master of Education in Counseling from Dallas Baptist University and has particular expertise working with special needs populations, including learning disabilities, ADHD, autism spectrum disorder, and emotional disturbance. Her background as a special education classroom teacher and elementary school counselor in Keller ISD for two decades provides her with unique insights into child development and the challenges families face.
The practice addresses a wide range of issues through evidence-based therapeutic techniques, including Cognitive Behavioral Therapy (CBT), play therapy, and Solution Focused Therapy (SFT). Common areas of treatment include anxiety, depression, ADHD, autism spectrum disorders, learning disabilities, trauma, behavioral issues, and family relationship challenges.
For women clients, Amy provides specialized support for anxiety and depression, PTSD and trauma recovery, menopause and hormonal changes, self-identity and self-worth issues, relationship challenges, and grief and loss.
For couples, she offers marriage counseling to help partners strengthen communication, rebuild trust, resolve conflicts, navigate parenting stress, and work through life transitions including healing from infidelity or emotional betrayal. Her approach combines evidence-based techniques to create a supportive and judgment-free environment where women and couples can develop effective coping strategies, build stronger relationships, and improve overall emotional well-being.
The new location reflects Amy Fowler Therapy's commitment to making quality mental health care accessible to families and couples in the North Texas area. The practice operates on a private-pay model with individual sessions priced at $115 for 50-minute sessions, and marriage counseling sessions at $125 for 50-minute sessions. The practice accepts HSA and FSA cards to help families manage healthcare costs. For families seeking child therapy services, an initial 90-minute parent intake session is required at $125, providing a comprehensive foundation for developing effective treatment plans.
Amy's approach emphasizes collaboration with parents, teachers, and other healthcare professionals to ensure comprehensive support for each client. This collaborative care model ensures that children receive consistent support across different environments, promoting their overall well-being and success in academic, social, and family settings.
The expansion comes at a time when mental health awareness and the need for accessible therapeutic services continue to grow throughout Texas communities. Mental health is a crucial part of a child's overall well-being, and early intervention can prevent minor issues from becoming major disorders, helping children lead healthier and more fulfilling lives. Similarly, for women juggling multiple roles and responsibilities, professional therapy provides crucial support to navigate life's challenges and foster personal growth. For couples facing relationship challenges, professional counseling offers tools to strengthen communication, rebuild trust, and create healthier partnerships.
Amy's approach to therapy is rooted in radical empathy, ensuring that every client feels deeply understood and supported. She is dedicated to creating a safe, nurturing environment where individuals can explore their emotions and challenges without judgment.
Amy Fowler Therapy is a private counseling practice serving children, teens, women, and couples in the Fort Worth area. Amy Fowler is a Licensed Professional Counselor Associate with specialized training in Trust-Based Relational Intervention for Trauma, Crisis Prevention Intervention, and Critical Incident Stress Debriefing. She holds a Bachelor of Science from Texas Christian University and a Master of Education from Dallas Baptist University, with additional certification from Lamar University.
The practice serves clients from throughout the North Texas region, including Fort Worth, Haslet, Keller, Saginaw, Rhome, and surrounding communities. Amy Fowler Therapy is committed to helping individuals and families find wholeness through compassionate, evidence-based therapeutic interventions.
Contact Information:
Amy Fowler Therapy 3348 Peden Rd., Suite 407 Fort Worth, TX 76179
For more information about services or to schedule an appointment, visit amyfowlertherapy.com or call the office directly.
###
For more information about Amy Fowler Therapy, contact the company here:Amy Fowler TherapyAmy Fowler817-239-9996info@amyfowlertherapy.comAmy Fowler Therapy3348 Peden Rd. Suite 407 Fort Worth, TX 76179
CONTACT: Amy Fowler
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research
Philadelphia-led consortium is selected to tailor HIV curative strategies to participant Philadelphia, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized 'cure regimens' for HIV. The Wistar-led, iCure Consortium's objective is to advance strategies to cure HIV through tailored personalized medicine. 'Today 38 million people still live with HIV worldwide, and 1.3 million contract the virus each year,' said Luis J. Montaner, D.V.M., iCure principal investigator, executive vice president of The Wistar Institute and director of Wistar's HIV Cure and Viral Diseases Center. 'For the first time, this grant brings our best team together working towards a cure tailored to each participant by pairing the latest in neutralizing antibody and cell-therapy breakthroughs against the unique, person-specific features of HIV.' iCure Consortium will test a six-part, individually-tailored therapy designed to wipe out the persistent viral reservoir that remains after antiretroviral therapy in an effort to deliver durable, drug-free remission. The project combines six advanced tactics—neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and 'Natural Killer' (NK) cells, and precision latency 'wake-up' drugs—all designed against each patient's unique virus. 'Ending HIV demands more than management—it demands eradication,' said Drew Weissman, M.D., Ph.D., iCure co‑principal investigator, 2023 Nobel Laureate and Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania. 'This project now allows us to apply our breakthroughs in RNA therapy as part of a cure-directed strategy.' How iCure Works• Wake the latent virus• Map and target unique weak spots with tailored antibodies• Destroy infected cells using 'super‑charged' CAR‑T and NK cells• Enhance clearance and block relapse with bispecific binders In the first step, researchers reactivate the virus in a sample of the participant's blood and identify mutations that the participant has not yet developed antibodies against. They then develop a tailored antibody therapy cocktail specifically designed against these specific mutations. In the next stage, researchers focus on preventing HIV from returning. To do this, they develop person-specific antibodies or small molecule binders that can act as 'homing devices' — beacons that can lead immune cells to the latent virus. Then they genetically modify CAR-T cells and NK cells (immune cells that destroy viruses) to express or use these homing devices to better clear infected cells. Finally, researchers further enhance NK cells. First, they develop stronger and more durable cells, called adaptive NK cells, by supercharging their virus-killing ability. Then, they deploy small-molecule drugs called bispecifics, which bind NK cells to the infected cells they are targeting. "iCure takes full advantage of the advances made in understanding how and where HIV hides from the immune system," said Montaner. "We've built on our knowledge and can use that information to identify a first of its kind targeting to a person's unique HIV features." iCure furthers the research groundwork laid by the BEAT-HIV Martin Delaney Collaboratory ( a Philadelphia-based consortium of more than 95 leading HIV researchers co-led by Dr. Montaner. Montaner called the NIH grant a 'once in a lifetime opportunity' that reflects Wistar's track record as a scientific leader in the effort to develop an HIV cure, as well as its grassroots support and collaboration with the HIV community. 'By the end of this study we hope to have a process by which to identify the virus that we need to go after in each person and have a basis to design clinical trials choosing the best of these strategies to move forward,' said Montaner. Other institutions participating in this study include Johns Hopkins Medicine and iCure co-principal investigator Robert Siliciano, M.D., Ph.D., the University of Pennsylvania, Philadelphia FIGHT, the Ragon Institute at Harvard University, George Washington University, Duke University, and Massachusetts Institute of Technology. The iCure program is funded by the National Institute of Allergy and Infectious Diseases, part of NIH, under award number UM1AI191272. ### The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 hours ago
- Yahoo
Rachelle Ramiro Breaks Down Energy, Clarity, and Control on The Health is A Skill Podcast with Todd Vande Hei
In this episode of Health is a Skill, Rachelle Ramiro shares how catching multiple myeloma early led to deeper self-awareness—and powerful healing tools like HBOT, exosomes, and radical self-care. Todd Vande Hei with guest Rachelle Ramiro on The Health is a Skill Podcast Beverly Hills California, Aug. 19, 2025 (GLOBE NEWSWIRE) -- On this new episode of Health is a Skill, host Todd Vande Hei welcomes Rachelle Ramiro, founder of CEO2 Health, for a revealing conversation about how a life-changing diagnosis reshaped her relationship with time, energy, and well-being. Diagnosed with multiple myeloma in her early 30s, Ramiro chose to take a proactive, multi-dimensional approach to healing. Speaking from inside a hyperbaric oxygen chamber, she details how early detection, unconventional therapies, and consistent recovery practices helped her normalize her labs, regain vitality, and stay fully engaged in both work and life. Key topics from the conversation include: Listening to your body: How Ramiro caught signs of cancer before her doctors did—beginning with elevated heart rate and night sweats. Hyperbaric oxygen therapy (HBOT): Why it became her foundation for lowering inflammation, improving sleep, and speeding recovery. Cutting-edge treatments: How exosomes, NAD+, and infrared saunas supported her immunity, cognitive clarity, and resilience. The danger of comfort: Why today's culture of ease is quietly undermining physical and mental health, and how embracing discomfort can heal. Reframing health: From cold plunges to meditation, Ramiro shares how discomfort, presence, and gratitude transformed her mindset and daily energy. Ramiro says, 'At one point, I couldn't even walk because of the pain. But after starting therapies like exosomes, I felt hopeful, mobile, and even joyful. I'm walking in Italy today because I chose to invest in my wellness.' The discussion also explores the growing role of mobile wellness: CEO2 Health now delivers hyperbaric oxygen therapy across homes, offices, events, and luxury spaces through portable chambers and custom installations. To learn more about personalized recovery and mobile hyperbaric therapy, visit About Health Is a SkillHealth is a Skill is a Los Angeles-based podcast hosted by Todd Vande Hei, CEO of Stark Health. Each episode blends scientific insight, personal stories, and actionable habits to show how optimizing healthspan can transform every decade of life. Media Communications: adamtorres@ Attachment Todd Vande Hei with guest Rachelle Ramiro on The Health is a Skill PodcastError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Yahoo
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg and 120 mg Addition of TUS to VEN+AZA improves MRD-negativity rates; 78% among responders 100% CR/CRh in FLT3 wildtype AML, representing 70% of AML population 100% CR/CRh and MRD-negativity rates in TP53, RAS and FLT3-ITD mutated AML Broad spectrum activity and excellent safety profile continue at 120 mg dose to date SAN DIEGO and TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ('Aptose' or the 'Company') (OTC: APTOF, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today provided a data update from the Phase 1/2 TUSCANY trial in newly diagnosed AML. The trial was initiated in December 2024, and the growing body of positive data includes the recently completed third cohort of 120 mg TUS in the TUS+VEN+AZA triplet therapy. Data to date from ten (10) patients across all three cohorts, 40 mg, 80 mg or 120 mg TUS dose in TUS+VEN+AZA, support the use of TUS with standard of care treatment across all AML populations, including those carrying mutations that are the most difficult to treat and those with mutated and unmutated (wildtype) FLT3 genes. The TUS+VEN+AZA triplet is being developed as a safe and well-tolerated mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. At the 120 mg TUS dose level in combination with VEN+AZA, as with the prior reported 40 mg and 80 mg TUS dose cohorts, no significant safety concerns or dose limiting toxicities (DLTs) have been observed in the TUSCANY trial, including no prolonged myelosuppression in Cycle 1 of subjects in remission, no reports of drug-related QTc prolongation or differentiation syndrome (DS), and no treatment-related deaths. Nine out of ten dosed patients remain on study across all dose cohorts and enrollment is being advanced to the 160 mg TUS dose level following the Cohort Safety Review Committee (CSRC) meeting. 'We already have data from three different TUS dose levels in the TUSCANY trial, and the data continue to strengthen at higher doses of TUS and over time. We are building a strong case for TUS+VEN+AZA as a triplet frontline therapy of choice to address a broad AML population, including subgroups with the most adverse of mutations,' said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. Data highlights: Comparison of CR/CRh1 Response rates2-5: VEN+AZA2 TUS+VEN+AZA All subjects 65% 90% (9/10) NPM1-mutant 67% 100% (2/2) FLT3-ITD 61% 100% (2/2) TP53-mutant 52% 100% (2/2) Comparison of MRD-negativity6 rates among All Subjects and among CR/CRh Responders3: VEN+AZA2,3 TUS+VEN+AZA Among All Subjects 23.4% 70% (7/10) Among CR/CRh Responders 40.9% 78% (7/9) Comparison of MRD-negativity rates among more difficult-to-treat Patient Subpopulations defined as Lower Benefit (TP53-mutated) and Intermediate Benefit (FLT3-ITD or RAS-mutated) relative to VEN+AZA5: VEN+AZA3,5 TUS+VEN+AZA Intermediate Benefit 27.9% 100% (3/3) Lower Benefit 14.5% 100% (2/2) TUS+VEN+AZA - CR/CRh and MRD-negativity rates among Subjects with Adverse Mutations: TP53, FLT3-ITD, RAS mutations: Achieved CR/CRh and MRD-negativity 100% (5/5) 'As illustrated in the data highlights, the addition of TUS to VEN+AZA appears to boost response rates and MRD-negativity while maintaining favorable safety and tolerability,' said Rafael Bejar, M.D., Ph.D., Chief Medical Officer of Aptose, 'and the 100% CR/CRh and 100% MRD-negativity rates among the five biallelic TP53-mutant, FLT3-ITD, and RAS-mutant AML cases are exciting to see, as this can correlate with longer overall survival. We have observed a trend towards achieving CRs more quickly at the higher dose levels, so we are keen to see the activity as we advance into the 160 mg TUS dose cohort.' Key messages: Addition of TUS to VEN+AZA demonstrates excellent CR/CRh rates 100% CR/CRh among all subjects treated at 80 mg and 120 mg TUS dose levels Appear to be achieving CR earlier with 120 mg TUS than with 40 mg or 80 mg Addition of TUS to VEN+AZA demonstrates excellent MRD-negativity rates MRD-negativity in 7 of 9 (78%) already achieved in patients who responded to therapy Expect patient survival to be extended with continued long-term treatment Excellent safety and well tolerated with no dose-limiting toxicities (No DLT) at completed dose levels Broad-spectrum activity including patients with adverse TP53, RAS and FLT3-ITD mutations No loss of MRD-negativity observed to date, including in one patient with over 7 months of follow up MRD-negativity and remissions continue to mature over time on therapy No relapses reported to date and no treatment related deaths The only non-responder was a patient at the initial TUS dose level (40 mg) that did not achieve TUS exposures previously associated with response Additional data are included in the new Aptose corporate presentation here. TUSCANY: TUS+VEN+AZA Triplet Phase 1/2 Study The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. The TUSCANY triplet Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by late 2025. Data will be released as it becomes available. More information on the TUSCANY Phase 1/2 study can be found on (here). About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the therapeutic potential and safety profile of tuspetinib (including the triplet therapy) and its clinical development, the anticipated enrollment rate in the TUSCANY trial and the timing thereof, as well as statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as 'continue', 'expect', 'intend', 'will', 'should', 'would', 'may', and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 'Risk Factors' in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences PietropaoloCorporate Communications & Investor Relations201-923-2049spietropaolo@ 1 Complete Response / Complete Response with Partial Hematological Recovery2 DiNardo et al. New England Journal of Medicine, August 2020; Volume 383(7):617-629.3 Pratz et al. Journal of Clinical Oncology, December 2021; Volume 40 (8):855-865.4 Othman et. al. Blood Neoplasia; September 2024; Volume 1 (3):1-11.5 Döhner et. al. Blood. 2024 November 21;144(21):2211-2222.6 MRD-negative indicates that the amount of Measurable Residual Disease, as assessed by central flow cytometry, is such that the proportion of leukemic cells in a bone marrow sample falls below <0.1%Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data